.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,326,383

« Back to Dashboard

Details for Patent: 6,326,383

Title: Medical use for tachykinin antagonists
Abstract:The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. ##STR1## wherein R represents the ring A ##STR2## or 2-pyridinyl or 2-pyridinyl-N-oxide; R.sup.1 is selected from halogen atoms and C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, and S(O).sub.n C.sub.1-4 alkyl groups; R.sup.2 and R.sup.3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
Inventor(s): Hagan; Russell Micheal (Ware, GB), Bunce; Keith Thomas (Ware, GB)
Assignee: Glaxo Group Limited (London, GB)
Filing Date:Sep 03, 1996
Application Number:08/706,836
Claims:1. A pharmaceutical composition for the treatment of emesis, comprsing:

an effective amount of an NK.sub.1 receptor antagonist of formula W: ##STR31##

wherein Y is (CH.sub.2).sub.n wherein n is an integer from 1 to 4, and wherein any one of the carbon-carbon single bonds in said (CH.sub.2).sub.n may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said (CH.sub.2).sub.n may optionally be substituted with R.sup.4 and wherein any one of the carbon atoms of said (CH.sub.2).sub.n may optionally be substituted with R.sup.7 ;

Z is (CH.sub.2).sub.m wherein m is an integer from 0 to 6, and wherein any one of the carbon-carbon single bonds of (CH.sub.2).sub.m may optionally be replaced by a carbon-carbon double bond or carbon-carbon triple bond, and any one of the carbon atoms of said (CH.sub.2).sub.m may optionally be substituted with R.sup.8 ;

R.sup.1 is hydrogen or (C.sub.1 -C.sub.8) alkyl optionally substituted with hydroxy, (C.sub.1 -C.sub.4) alkoxy or fluoro;

R.sup.2 is a radical selected from hydrogen, (C.sub.1 -C.sub.6) straight or branched alkyl, (C.sub.3 -C.sub.7) cycloalkyl wherein one of the CH.sub.2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulfur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isaoxazolyl, triazolyl, tetrazolyl and quinolyl; phenl-(C.sub.2 -C.sub.6)-alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl-(C.sub.2 -C.sub.6)-alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, trifluoromethyl, amino, (C.sub.1 -C.sub.6)-alkylamino, (C.sub.1 -C.sub.6) alkyl-O--C(O)--, (C.sub.1 -C.sub.6)alkyl-O--C--(O)--(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl-C(O)--O--, (C.sub.1 -C.sub.6)alkyl-C(O)--, (C.sub.1 -C.sub.6)alkyl-O--, (C.sub.1 -C.sub.6)alkyl-C(O)--, (C.sub.1 -C.sub.6)alkyl-C(O)--(C.sub.1 -C.sub.6)alkyl--, di-(C.sub.1 -C.sub.6)alkylamino, --CONH--(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)-alkyl--CONH--(C.sub.1 -C.sub.6)alkyl, NHC(O)H and --NHC(O)--(C.sub.1 -C.sub.6) alkyl; and

wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R.sub.5 is hydrogen, phenyl or (C.sub.1 -C.sub.6) alkyl; or

R.sup.2 and R.sup.5, together with the carbon to which they are attached, form a saturated ring having from 3 to 7 carbon atoms wherein one of the CH.sub.2 groups in said ring may optionally be replaced by oxygen, NH or sulfur;

R.sup.3 is aryl selected from phenyl and naphthyl; heteoaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl; tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms wherein one of the (CH.sub.2) groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulfur;

wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said (C.sub.3 -C.sub.7) cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, trifluoromethyl, amino, (C.sub.1 -C.sub.6) alkylamino, --CONH--(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl-C(O)--NH--(C.sub.1 -C.sub.6)alkyl, --NHC(O)H and --NHC(O)--(C.sub.1 -C.sub.6)alkyl; and

R.sup.4 and R.sup.7 are each independently selected from hydroxy, hydrogen, halo, amino, oxo, cyano, methylene, hydroxymethyl, halomethyl, (C.sub.1 -C.sub.6)alkylamino, di-(C.sub.1 -C.sub.6)alkylamino, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkyl-O--C(O)--, (C.sub.1 -C.sub.6)alkyl-O--C(O)--(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl-C(O), (C.sub.1 -C.sub.6)alkyl-C--(O)--(C.sub.1 -C.sub.6)alkyl-O, (C.sub.1 -C.sub.6)alkyl-C(O), (C.sub.1 -C.sub.6)alkyl-C(O)--(C.sub.1 -C.sub.6)alkyl--, and

the radicals set forth in the definition of R.sup.2, R.sup.6 is NHC(O)R.sup.9, --NHCH.sub.2 R.sup.9, SO.sub.2 R.sup.9 or one of the radicals set forth in any of the definitions or R.sup.2, R.sup.4 and R.sup.7 ;

R.sup.8 is oximino (.dbd.NOH) or one of the radicals set forth in any of the definitions of R.sup.2, R.sup.4 and R.sup.7 ;

R.sup.9 is (C.sub.1 -C.sub.6)alkyl, hydrogen, phenyl or phenyl(C.sub.1 -C.sub.6)alkyl; with the proviso that (a) when m is O, R.sup.8 is absent, (b) when R.sup.4, R.sup.6, R.sup.7, or R.sup.8 is as defined in R.sup.2, it cannot form, together with the carbon to which it is attached, a ring with R.sup.5, and (C) when R.sup.4 and R.sup.7 are attached to the same carbon atom, then either each of R.sup.4 and R.sup.7 is independently selected from hydrogen, fluoro and (C.sub.1 -C.sub.6) alkyl, or R.sup.4 and R.sup.7, together with the carbon to which they are attached, form a (C.sub.3 -C.sub.6) saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached; and pharmaceutically acceptable acid addition salts thereof,

in combination with an effective amount of a 5HT.sub.3 antagonist which is selected from the group consisting of ondansetron, metoclopramide and granisetron.

2. A pharmaceutical composition for the treatment of emesis, comprising:

an effective amount on NK.sub.1 antagonist which is cis-3-(2-methoxybenzylamino)-2-phenyl piperidine; and

an effective amount of 5HT.sub.3 antagonist which is ondansetron.

3. A method for the treatment of emesis in a mammal, comprising the steps of:

administering to said mammal an effective amount of an NK.sub.1 receptor antagonist of the formula W: ##STR32##

wherein Y is (CH.sub.2).sub.n wherein n is an integer from 1 to 4, and wherein any one of the carbon-carbon single bonds in said (CH.sub.2).sub.n may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said (CH.sub.2).sub.n may optionally be substituted with R.sup.4 and wherein any one of the carbon atoms of said (CH.sub.2).sub.n may optionally be substituted with R.sup.7 ;

Z is (CH.sub.2).sub.m wherein m is an integer from 0 to 6, and wherein any one of the carbon-carbon single bonds of (CH.sub.2).sub.m may optionally be replaced by a carbon-carbon double bond or carbon-carbon triple bond, and any one of the carbon atoms of said (CH.sub.2).sub.m may optionally be substituted with R.sup.8 ;

R.sup.1 is hydrogen or (C.sub.1 -C.sub.8) alkyl optionally substituted with hydroxy, (C.sub.1 -C.sub.4) alkoxy or fluoro;

R.sup.2 is a radical selected from hydrogen, (C.sub.1 -C.sub.6) straight or branched alkyl, (C.sub.3 -C.sub.7) cycloalkyl wherein one of the CH.sub.2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulfur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isaoxazolyl, triazolyl, tetrazolyl and quinolyl; phenl-(C.sub.2 -C.sub.6)-alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl-(C.sub.2 -C.sub.6)-alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, trifluoromethyl, amino, (C.sub.1 -C.sub.6)-alkylamino, (C.sub.1 -C.sub.6) alkyl-O--C(O)--, (C.sub.1 -C.sub.6)alkyl-O--C--(O)--(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl-C(O)--O--, (C.sub.1 -C.sub.6)alkyl-C(O)--, (C.sub.1 -C.sub.6)alkyl-O--, (C.sub.1 -C.sub.6)alkyl-C(O)--, (C.sub.1 -C.sub.6)alkyl-C(O)--(C.sub.1 -C.sub.6)alkyl--, di-(C.sub.1 -C.sub.6)alkylamino, --CONH--(C.sub.1-6)alkyl, (C.sub.1 -C.sub.6)-alkyl--CONH--(C.sub.1 -C.sub.6)alkyl, NHC(O)H and --NHC(O)--(C.sub.1 -C.sub.6) alkyl; and

wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R.sub.5 is hydrogen, phenyl or (C.sub.1 -C.sub.6) alkyl; or R.sup.2 and R.sup.5, together with the carbon to which they are attached, form a saturated ring having from 3 to 7 carbon atoms wherein one of the CH.sub.2 groups in said ring may optionally be replaced by oxygen, NH or sulfur;

R.sup.3 is aryl selected from phenyl and naphthyl; heteoaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl; tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms wherein one of the (CH.sub.2) groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulfur;

wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said (C.sub.3 -C.sub.7) cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, trifluoromethyl, amino, (C.sub.1 -C.sub.6) alkylamino, --CONH--(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl-C(O)--NH--(C.sub.1 -C.sub.6)alkyl, --NHC(O)H and --NHC(O)--(C.sub.1 -C.sub.6)alkyl; and

R.sup.4 and R.sup.7 are each independently selected from hydroxy, hydrogen, halo, amino, oxo, cyano, methylene, hydroxymethyl, halomethyl, (C.sub.1 -C.sub.6)alkylamino, di-(C.sub.1 -C.sub.6)alkylamino, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkyl-O--C(O)--, (C.sub.1 -C.sub.6)alkyl-O--C(O)--(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl-C(O), (C.sub.1 -C.sub.6)alkyl-C--(O)--(C.sub.1 -C.sub.6)alkyl-O, (C.sub.1 -C.sub.6)alkyl-C(O), (C.sub.1 -C.sub.6)alkyl-C(O)--(C.sub.1 -C.sub.6)alkyl--, and

the radicals set forth in the definition of R.sup.2, R.sup.6 is NHC(O)R.sup.9, --NHCH.sub.2 R.sup.9, SO.sub.2 R.sup.9 or one of the radicals set forth in any of the definitions or R.sup.2, R.sup.4 and R.sup.7 ;

R.sup.8 is oximino (.dbd.NOH) or one of the radicals set forth in any of the definitions of R.sup.2, R.sup.4 and R.sup.7 ;

R.sup.9 is (C.sub.1 -C.sub.6)alkyl, hydrogen, phenyl or phenyl(C.sub.1 -C.sub.6)alkyl; with the proviso that (a) when m is O, R.sup.8 is absent, (b) when R.sup.4, R.sup.6, R.sup.7, or R.sup.3 is as defined in R.sup.2, it cannot form, together with the carbon to which it is attached, a ring with R.sup.5, and (C) when R.sup.4 and R.sup.7 are attached to the same carbon atom, then either each of R.sup.4 and R.sup.7 is independently selected from hydrogen, fluoro and (C.sub.1 -C.sub.6) alkyl, or R.sup.4 and R.sup.7, together with the carbon to which they are attached, form a (C.sub.3 -C.sub.6) saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached; and pharmaceutically acceptable acid addition salts thereof,

in combination with an effective amount of a 5HT.sub.3 antagonist which is selected from the group consisting of ondansetron, metoclopramide and granisetion.

4. A method for the treatment of emesis in a mammal comprising administering to said mammal an effective amount of an NK.sub.1 antagonist which is cis-3-(2-methoxybenzylamino)-2-phenyl piperidine in combination with a 5HT.sub.3 antagonist which is ondansetron.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc